EPIDEMIOLOGICAL DESCRIPTION OF CHRONIC OBSTRUCTIVE LUNG DISEASE IN FERGONA VALLEY AND DETERMINATION OF ITS 10-YEAR CHANGING TREND

Tajibaeva Laylo Rustamovna

Authors

Tajibaeva Laylo Rustamovna

Abstract

The last ten in the world chronic obstructive pulmonary disease during the year (Epidemiological conditions and environmental conditions have changed dramatically[1, 4, 9, 11, 14]. Taking this into account, it is a world science to develop and modify appropriate prevention and treatment practices on a scientific basis[5, 10, 13], including the changing climatic, ecological and medical conditions of Uzbekistan, is a need, necessity and urgent topic.

References

Avdeev SN, Trushenko NV Triple therapy in the treatment of chronic obstructive pulmonary disease // Pulmonology, 2019. – 29 (2): 199 – 206.

Avdeev SN, Trushenko NV New triple combination of beclomethasone dipropionata, glycopyrrolate bromide and farmoterol fumarate in chronic obstructive pulmonary disease // Pulmonology, 2001. Volume 31. No. 3. P. 365 – 371.

Alekseeva OV, Demko IV, Schneider IA, Petrova MM Komorbidnost sindroma obstruktivnogo apnoe/hypopnoe sna i chronicheskoy obstruktivnogo bolozni legkix // Zaboykalsky medical journal, 2016. №2. - P. 107-114.

Aleksandrov OV Gazovaya therapy and pulmonology // Klin. Medicine, 2004. Volume 72. No. 1.–P. 30–34.

Ansev EX, Chuchalin AG pulmonary eosinophilia: diagnosis, treatment // Pulmonology, 2012; (4): 100–115. DOI: 10: 18093/0869–0189–2012–0–106–115.

Aysanov ZR, Avdeev SN, Arkhipov VV and dr. National clinical recommendations for diagnosis and treatment of chronic obstructive pulmonary disease: algorithm for clinical decision // Pulmonology, 2017; 27 (1): 13 – 20. DOI: 10. 18093/0869 – 0189. 2017–27–1–13–20.

Achakov AI Microsomal oxidation. - M: Nauka, 2005. - S 127.

Bogdanov D.Yu., Kondrashova EA, Kulakova NV and dr. Characteristics of risk factors for cardiovascular and cerebrovascular diseases and populations. Primarskogo kraya v zavisimosti ot status kurenia i vozrasta (po dannim epidemiologicheskogo issledovaniya ESSE – RF) // Tikhookeansky medical journal, 2017 (4): 45 – 50.

Bistriskaya EV, bilichenko TN Zabolevaemost, invalidnost i smertnost ot bolezney organov dikhaniya v Rossiyskoy Federasiii (2015–2019) // Pulmonology, 2021. –31 (5): 551–561. DOI: 10. 18093/0869–0189–2021–31–5–551–561.

Vasileva OS, Kuzmina LP, Chernyak AV, Kravchenko N.Yu., Kolyaskina MM The professional factor and the role of individual vospriimchivosti k razvitiyu i techeniyu broncholegochnix zabolevaniy // Pulmonology, 2021. Volume 31. No. 4. – S. 463–468.

Leshenko IV Vozmojenosti i ogranichenia primeneniya ingalyasionnix glucocorticosteroidov v terapii kronicheskoy obstructive obsektivnoi legkix // Pulmonology, 2018. Volume 28. No. 5. – S. 603–612.

European Lung with Book Occupational risk factors. Available at: https: // www. Erswhitebool.org/chapers/occupational.risk.factors/ [Accessed/ July; 2018].

Miillerova H., Maselli DJ, Locantore N. et al. hospitalized exacerbations of the ECLIPSE cohort // chest - 2015; 147(4):999–1007.

Shahab L., Jarvis MJ, Britton S., West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample // Thorax, 2006. Njv 61 - # 12: 1043–104.

Xie J., Li., Wu X., Hou W. Prevalence of pulmonary embolism in patients with obstructive sleep apnea and chronic obstructive pulmonary disease: The overdiap syndrome. Heart Lang–2019. - 48 (3): 261–263.